Clinicopathological features and outcomes after radioactive iodine treatment of oncocytic well-differentiated thyroid carcinomas

Amouri, W.; Charfeddine, S.; Jardak, I.; Boudawara, Tahia; Guermazi, F.

doi:10.1097/mnm.0000000000001049

Cited by 5 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then, 0.8 µg Kd-Vdr and Kd-nc plasmids, as well as the packaging plasmids prSV/preV (addgene, inc.), pcMV-VSV-G (addgene, inc.) and pMdlG/prre (addgene, inc.), were co-transfected into 2x10 5 293T cells using lipofectamine ® 2000 reagent (Thermo Fisher Scientific, inc.) and the lentiviral particles were harvested after 48 h by centrifugation (30,000 x g; 4˚C; 4 h). A total of 1x10 5 Snu-790 and 1x10 5 iHH4 cells were infected with the lentiviral particles (Moi=20 and 40, respectively) in the presence of 8 µg/ml polybrene (Sigma-Aldrich; Merck KGaA) at 37˚C for 24 h, and then stably infected cells were selected using puromycin (Thermo Fisher Scientific, Inc.) for 7 days.…”

Section: Methodsmentioning

confidence: 99%

“…Papillary thyroid cancer (PTc) is the most common type of thyroid cancer and accounts for ~90% of all thyroid cancer cases (3). Although the majority of patients with PTC benefit from surgery, levothyroxine and radioactive iodine therapy, certain patients still experience a high rate of metastasis and recurrence (4)(5)(6)(7). Therefore, understanding the mechanisms underlying the development and progression of PTc may aid the development of novel therapies in the future.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vitamin D receptor knockdown attenuates the antiproliferative, pro‑apoptotic and anti‑invasive effect of vitamin D by activating the Wnt/β‑catenin signaling pathway in papillary thyroid cancer

Pang

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

Vitamin d and the vitamin d receptor (Vdr) complex have been reported to inhibit the growth of several types of tumor; however, their function in papillary thyroid cancer (PcT) remains unknown. in addition, the Wnt/β-catenin signaling pathway was discovered to serve a critical role in the pathology of PcT. Therefore, the present study aimed to determine the role of the Vdr and its association with Wnt/β-catenin signaling in vitamin d-treated PTc cells. Vdr expression was detected in human PTc cells (including Mda-T120, Mda-T85, Snu-790 and iHH4 cells) and thyroid follicular cells (nthy-ori 3-1 cells). Snu-790 and iHH4 cells were infected with Kd-Vdr or negative control (Kd-nc) lentiviruses, treated with 1,25(oH) 2 d3 (the active form of vitamin d), and subsequently referred to as the Kd-Vdr&vitd and Kd-nc&vitd groups, respectively. additionally, PTc cells infected with Kd-nc and not treated with 1,25(oH) 2 d3 were used as the normal control and referred to as the Kd-nc group. Vdr mrna and protein expression levels were increased in Mda-T120, Snu-790 and Mda-T85 cells compared to nthy-ori 3-1 cells, whereas in iHH4 cells, Vdr mrna and protein expression levels were similar to nthy-ori 3-1 cells. in Snu-790 and iHH4 cells, cell proliferation and invasion were decreased in the Kd-nc&vitd group compared with the Kd-nc group, but increased in the Kd-Vdr&vitd group compared with the Kd-nc&vitd group. cell apoptosis was increased in the Kd-nc&vitd group compared with the Kd-nc group, and decreased in the Kd-Vdr&vitd group compared with the Kd-nc&vitd group. Furthermore, the expression levels of Wnt family member 3 and catenin β1 were decreased in the Kd-nc&vitd group compared with the Kd-nc group, but increased in the Kd-Vdr&vitd group compared with the Kd-nc&vitd group. in conclusion, the present study revealed that Vdr-Kd attenuated the antiproliferative, pro-apoptotic and anti-invasive effects of vitamin d in PTc by activating the Wnt/β-catenin signaling pathway.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Vitamin D receptor knockdown attenuates the antiproliferative, pro‑apoptotic and anti‑invasive effect of vitamin D by activating the Wnt/β‑catenin signaling pathway in papillary thyroid cancer

Pang

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

show abstract

“…First, there was no control group, and the HCC cases included in the study were largely minimally invasive cancers, which are likely to exhibit excellent outcomes regardless of intervention. The study was not able to discriminate between cervical neck RAI uptake from normal thyroid remnant or residual cancer, and no patients developed metastases in which uptake could be directly examined ( 69 ).…”

Section: Clinical Challengesmentioning

confidence: 99%

Genetics, Diagnosis, and Management of Hürthle Cell Thyroid Neoplasms

McFadden

Sadow

2021

Front. Endocrinol.

View full text Add to dashboard Cite

Hürthle cell lesions have been a diagnostic conundrum in pathology since they were first recognized over a century ago. Controversy as to the name of the cell, the origin of the cell, and even which cells in particular may be designated as such still challenge pathologists and confound those treating patients with a diagnosis of “Hürthle cell” anything within the diagnosis, especially if that anything is a sizable mass lesion. The diagnosis of Hürthle cell adenoma (HCA) or Hürthle cell carcinoma (HCC) has typically relied on a judgement call by pathologists as to the presence or absence of capsular and/or vascular invasion of the adjacent thyroid parenchyma, easy to note in widely invasive disease and a somewhat subjective diagnosis for minimally invasive or borderline invasive disease. Diagnostic specificity, which has incorporated a sharp increase in molecular genetic studies of thyroid tumor subtypes and the integration of molecular testing into preoperative management protocols, continues to be challenged by Hürthle cell neoplasia. Here, we provide the improving yet still murky state of what is known about Hürthle cell tumor genetics, clinical management, and based upon what we are learning about the genetics of other thyroid tumors, how to manage expectations, by pathologists, clinicians, and patients, for more actionable, precise classifications of Hürthle cell tumors of the thyroid.

show abstract

“…Review of data on “Hürthle cell” carcinomas in the National Cancer Data Base from 1998 to 2006 identified that the use of RAI improved survival at 10 years from 65.0% to 74.4% (p<0.001) ( 6 ). One retrospective study showed uptake by metastatic disease in greater than 70% of patients with distant metastasis (DM) at presentation supporting the use of RAI in this patient population ( 10 ). These data suggest that there may be an indication for the use of RAI in the management of patients with oncocytic thyroid cancers, although there remains ongoing uncertainty.…”

Section: Introductionmentioning

confidence: 99%

“…Additionally, the published data do not meticulously distinguish the various types of oncocytic thyroid cancers including follicular variant and classical papillary thyroid carcinomas (PTCs), follicular thyroid carcinoma (oncocytic/Hürthle cell thyroid carcinoma), and poorly differentiated thyroid carcinomas (PDTCs) ( 11 ). The scant data on clinicopathologic characteristics of oncocytic PTCs stem from small clinical series ( 1 , 7 , 10 , 12 – 14 ). In some cohorts, patients with oncocytic PTC had more frequent locally invasive growth, extra-thyroidal extension and lymph node metastasis ( 1 , 10 , 14 ).…”

Section: Introductionmentioning

confidence: 99%

Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome

et al. 2021

View full text Add to dashboard Cite

ObjectiveThe main objective of this study was to review the clinicopathologic characteristics and outcome of patients with oncocytic papillary thyroid carcinoma (PTC) and oncocytic poorly differentiated thyroid carcinoma (PDTC). The secondary objective was to evaluate the prevalence and outcomes of RAI use in this population.MethodsPatients with oncocytic PTC and PDTC who were treated at a quaternary cancer centre between 2002 and 2017 were retrospectively identified from an institutional database. All patients had an expert pathology review to ensure consistent reporting and definition. The cumulative incidence function was used to analyse locoregional failure (LRF) and distant metastasis (DM) rates. Univariable analysis (UVA) was used to assess clinical predictors of outcome.ResultsIn total, 263 patients were included (PTC [n=218], PDTC [n=45]) with a median follow up of 4.4 years (range: 0 = 26.7 years). Patients with oncocytic PTC had a 5/10-year incidence of LRF and DM, respectively, of 2.7%/5.6% and 3.4%/4.5%. On UVA, there was an increased risk of DM in PTC tumors with widely invasive growth (HR 17.1; p<0.001), extra-thyroidal extension (HR 24.95; p<0.001), angioinvasion (HR 32.58; p=0.002), focal dedifferentiation (HR 19.57, p<0.001), and focal hobnail cell change (HR 8.67, p=0.042). There was additionally an increased risk of DM seen in male PTC patients (HR 5.5, p=0.03).The use of RAI was more common in patients with larger tumors, angioinvasion, and widely invasive disease. RAI was also used in the management of DM and 43% of patients with oncocytic PTC had RAI-avid metastatic disease. Patients with oncocytic PDTC had a higher rate of 5/10-year incidence of LRF and DM (21.4%/45.4%; 11.4%/40.4%, respectively). Patients with extra-thyroidal extension had an increased risk of DM (HR 5.52, p=0.023) as did those with angioinvasion. Of the patients with oncocytic PDTC who received RAI for the treatment of DM, 40% had RAI-avid disease.ConclusionWe present a large homogenous cohort of patients with oncocytic PTC and PDTC, with consistent pathologic reporting and definition. Patients with oncocytic PTC have excellent clinical outcomes and similar risk factors for recurrence as their non-oncocytic counterparts (angioinvasion, large tumor size, extra-thyroidal extension, and focal dedifferentiation). Compared with oncocytic PTCs, the adverse biology of oncocytic PDTCs is supported with increased frequency of DM and lower uptake of RAI.

show abstract

Clinicopathological features and outcomes after radioactive iodine treatment of oncocytic well-differentiated thyroid carcinomas

Cited by 5 publications

References 27 publications

Vitamin D receptor knockdown attenuates the antiproliferative, pro‑apoptotic and anti‑invasive effect of vitamin D by activating the Wnt/β‑catenin signaling pathway in papillary thyroid cancer

Vitamin D receptor knockdown attenuates the antiproliferative, pro‑apoptotic and anti‑invasive effect of vitamin D by activating the Wnt/β‑catenin signaling pathway in papillary thyroid cancer

Genetics, Diagnosis, and Management of Hürthle Cell Thyroid Neoplasms

Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome

Contact Info

Product

Resources

About